The Gerald J. Glasser Brain Tumor Center offers patients hope through a robust clinical trial research program. Researchers are working to discover the next generation of brain tumor treatments.
This phase II trial studies how well genetic testing works in guiding treatment for patients with solid tumors that have spread to the brain. These brain metastases often have altered or mutated genes. Medications that target these genes may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
For Newly-Diagnosed Patients
For Newly-Diagnosed Patients
For Patients With Recurrent Glioblastoma
This phase II study examines immunotherapy drugs ipilimumab and nivolumab in patients with glioblastoma that has recurred and carries a high number of mutations. These immunotherapy medications with monoclonal antibodies may help the body's immune system attack cancerous cells and may interfere with tumor cells’ ability to grow and spread.
For Patients With Recurrent Glioblastoma
For Patients With Recurrent Glioblastoma
This phase II study examines immunotherapy drugs Tocilizumab and Atezolizumab and stereotactic radiation therapy in patients with glioblastoma that has recurred after initial treatment. These immunotherapy medications with monoclonal antibodies may help the body's immune system attack cancerous cells and may interfere with tumor cells’ ability to grow and spread.